Remygen (oral GABA) — Diamyd's beta-cell regeneration bet
Diamyd Medical (Uppsala University investigator-led trials)
What it is
Remygen is Diamyd Medical's controlled-release oral form of GABA, a molecule that in lab and animal studies coaxes beta cells to multiply and calms islet inflammation. It was tested as a stand-alone way to regrow insulin production in people with long-standing T1D. In the completed ReGenerate-1 trial it showed no measurable beta-cell regeneration. Liver-enzyme elevations occurred in nine of 35 participants and two withdrew; this is a negative human result with safety limitations.
Editorial review: .
Most recent recorded citation date: 2025-04-04. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Regrowth efficacy: In the completed adult ReGenerate-1 RCT, GABA produced no change in fasting or stimulated C-peptide, CGM metrics or HbA1c — no clinical evidence of beta-cell regeneration.[1]
- Important harms and treatment burden
- Safety: Generally tolerable, but nine of 35 adults had elevated liver enzyme (AST) levels and two withdrew; a separate pediatric GABA/GAD trial confirmed broad tolerability.[1]
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: With no measurable beta-cell gain to sustain over 6 months of dosing, durability is moot; any regrown cells would also still face ongoing autoimmunity (site reasoning; not stated in the fetched abstract).[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 8 × 30 + 5 × 15 + 55 × 15 + 60 × 15 + 30 × 25 = 2790; divide by total weight 100. Unrounded weighted result: 27.9.
In the completed adult ReGenerate-1 RCT, GABA produced no change in fasting or stimulated C-peptide, CGM metrics or HbA1c — no clinical evidence of beta-cell regeneration.[1]
With no measurable beta-cell gain to sustain over 6 months of dosing, durability is moot; any regrown cells would also still face ongoing autoimmunity (site reasoning; not stated in the fetched abstract).[1]
Generally tolerable, but nine of 35 adults had elevated liver enzyme (AST) levels and two withdrew; a separate pediatric GABA/GAD trial confirmed broad tolerability.[1]
A cheap oral pill would in principle reach almost anyone, but it showed no group-level benefit — and the regeneration premise needs residual beta cells to act on (cost and residual-cell premises are site reasoning; fetched text establishes oral daily dosing with no group-level C-peptide/CGM/HbA1c effect).[2]
Reached completed, registered phase I/II human trials (NCT03635437) — further than most regeneration ideas — but those trials read out negative for beta-cell function.[3]
The full picture
GABA is the molecule that, in dishes and mice, ticks every box you would want from a beta-cell regeneration drug: it nudges beta cells to multiply, boosts insulin release, dampens alpha-cell glucagon, and quiets islet inflammation. Diamyd Medical built a controlled-release oral form, Remygen, to test whether that promise carries into people. the registry-listed 'Regenerate-1' trial, run at Uppsala University, gave Remygen once daily for six months to adults who had lived with T1D for at least five years and had little or no insulin production left — exactly the group a true regeneration drug would need to help.
The honest result: it did not work as a regenerative therapy. Fasting and meal-stimulated C-peptide, continuous-glucose metrics and HbA1c were all unchanged, so there was no sign that beta cells came back. Side effects were common, including transient liver-enzyme rises in nine of 35 participants, two of whom withdrew. An earlier pediatric trial of oral GABA, alone or with the GAD-alum vaccine, in newly diagnosed children likewise missed its goal of preserving C-peptide, with reassuring tolerability in that paediatric study. Lower doses or short exposure were proposed as possible explanations for negative findings, but no explanation has been established and higher doses cannot be assumed effective or safer. Remygen matters here as a cautionary, well-documented negative — a reminder that elegant mouse biology often stalls in humans.
Coming soon
ETA · No regenerative effect seen in the completed phase I/II trial; no further regeneration trial of GABA announced in the checked sources. Not a near-term therapy as assessed here.
- →Higher-dose or longer-acting GABA formulations (suggested by investigators, not yet trialled)
- →GABA paired with antigen-specific immunotherapy (e.g. GAD-alum) rather than used alone (pairing already tested in the pediatric GABA+/-GAD-alum trial, which missed its C-peptide primary)
Sources
- [1]Long-term gamma-aminobutyric acid (GABA) treatment fails to regain beta-cell function in longstanding type 1 diabetes in a randomized trial · Peer-reviewed study · 2025-04-04
- [2]
- [3]